Eupraxia Pharmaceuticals (EPRX) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eupraxia Pharmaceuticals is the larger company by market cap ($495.9 million vs $488.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EPRX | MPLT |
|---|---|---|
| Share price | $7.51 | $8.78 |
| Market cap | $495.88M | $487.95M |
| 1-day change | -0.86% | -4.04% |
| YTD return | +0.26% | -47.91% |
| 1-year return | +23.29% | — |
| EPS (TTM) | $-1.02 | $-6.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.32 | $40.43 |
| 52-week low | $5.25 | $8.74 |
| Distance from 52-week high | -19.47% | -78.28% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +117.85% | +202.28% |
| Average volume | 575.10K | 851.70K |
| Shares outstanding | 66.07M | 52.85M |
| Employees | 49 | 133 |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
EPRX vs MPLT FAQ
Which is bigger, Eupraxia Pharmaceuticals or MapLight Therapeutics?
Eupraxia Pharmaceuticals (EPRX) is larger, with a market capitalization of $495.88M compared with $487.95M for MapLight Therapeutics (MPLT).
Are Eupraxia Pharmaceuticals and MapLight Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for MapLight Therapeutics.